Gilead Finalizes Selection of Bioequivalent for Fixed-Dose Truvada and Tibotec’s TMC278

Gilead Sciences, Inc. announced Tuesday it has obtained data supporting bioequivalence of a formulation of the fixed-dose combination of Truvada (emtricitabine and tenofovir disoproxil fumarate) and Tibotec Pharmaceuticals’ investigational non-nucleoside reverse transcriptase inhibitor TMC278 (rilpivirine hydrochloride, 25 mg).
Forbes